Binase and other microbial RNases as potential anticancer agents

BioEssays

Volumn 30, Issue 8, 2008, Pages 781-790

  Makarov, Alexander A ^a   Kolchinsky, Alexander ^c   Ilinskaya, Olga N ^a,b  

^a ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^b KAZAN FEDERAL UNIVERSITY   (Russian Federation)

^c Health Front Line Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA SARCIN; ANTINEOPLASTIC AGENT; BARNASE; BINASE; BLEOMYCIN; CETUXIMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; PANITUMUMAB; RANPIRNASE; RIBONUCLEASE; RITUXIMAB; TOSITUMOMAB; TRASTUZUMAB;

ANTIGENICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACILLUS; BACILLUS INTERMEDIUS; CANCER CELL; CANCER CELL CULTURE; CHEMICAL MODIFICATION; CYTOTOXICITY; DRUG APPROVAL; DRUG MECHANISM; DRUG PENETRATION; DRUG SELECTIVITY; GENETIC MANIPULATION; HUMAN; NONHUMAN; STREPTOMYCES AUREOFACIENS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BACILLUS; BACTERIA; ENDORIBONUCLEASES; HUMANS; MICE; MODELS, BIOLOGICAL; MODELS, MOLECULAR; NEOPLASMS; PROTEIN STRUCTURE, SECONDARY; RIBONUCLEASES; STREPTOMYCES AUREOFACIENS; TIME FACTORS;

ANURA; BACILLUS INTERMEDIUS; STREPTOMYCES AUREOFACIENS;

EID: 48949094215     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.20789     Document Type: Article

References (78)

1. Matousek J. 2001. Ribonucleases and their antitumor activity. Comp Biochem Physiol C Toxicol Pharmacol 129:175-191.
2. Vescia S, Tramontano D, Augusti-Tocco G, D'Alessio G. 1980. In vitro studies on selective inhibition of tumor cell growth by seminal ribonuclease. Cancer Res 40:3740-3744.
3. Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt WJ, Shogen K. 1988. Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent. Cell Tissue Kinet 21:169-182.
4. Lee JE, Raines RT, 2008. Ribonuclealses as novel chemotherapeutics: the ranpirnase example. BioDrugs 22:63-58.
5. Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub RN et at, 2002. Phase II trial of a single weekly intravenous dose of rapimase in patient with unresectable malignant mesothelioma. J. Clin Oncol 20: 274-281.
6. Alfacell Corporation. Alfacell Provides Update on ONCONASE Phase IIIb Confirmatory Registration Trial; Releases First Interim Analysis Data. Media Release: 27 April 2006. Available from URL http://www.alfacell.com Accessed April 27, 2007.
7. Ranpirnase amphibian ribanuclease A. P-30 protein - Alfacell 2007. Drugs R and D 8:120-124.
8. Belyaeva MI, Kyune MF, Nuzhina AM. 1964. Effect of bacterial deoxyribonuclease on Ehrlich's ascites carcinoma cells in vitro. Fed Proc Transl Suppl 23:345-348.
9. Aphanasenko GA, Dudkin SM, Kaminir LB, Leshchinskaya IB, Severin ES. 1979. Primary structure of ribonuclease from Bacillus intermedius7P. 97:77-80.
10. Schulga AA, Nurkiyanova KM, Zakharyev VM, Kirpichnikov MP, Skryabin KG. 1992. Cloning of the gene encoding RNase binase from Bacillus intermedius7P. Nucleic Acids Res 20:2375.
11. Polyakov KM, Lebedev AA, Okorokov AL, Panov KI, Schulga AA et al. 2002. The structure of substrate-free microbial ribanuclease binase and of its complexes with 3'GMP and sulfate ions, Acta Cryst Section D 58: 744-750.
12. Johnson RJ, Lavis LD, Raines RT, 2007. Intraspecies regulation of ribonucleolytic activity. Biochemistry 46:13131-13140.
13. Hartley RW. 1988. Bamase and barstar. Exp~ession of its cloned inhibitor permits expression of a cloned ribonuclease. J. Mol Biol 202:913-915.
14. Yakovlev GI, Moiseyev GP, Protasevich II, Ranjbar B, Bocharov AL et al. 1995. Dissociation constants and thermal stability of complexes of Bacillus intermedius RNase and the protein inhibitor of Bacillus amyloliquefaciens RNase. FEBS Letters 366:156-158.
15. Sevcik J, Urbanikova L, Leland PA, Raines RT. 2002. X-Ray structure of two crystalline forms of a streptomycete ribonuclease with cytotoxic activity. J. Biol Chem 277:47325-47330.
16. Cho S, Joshi JG, 1989. Ribonuclease inhibitor from pig brain: Purification, characterization, and direct spectrophotometric assay. Anal Biochem 176:175-179.
17. II'inskaia ON, Krylova NI. 1993. [The action of Oxogenous RNAse on the cells of lower eukaryotes] Prikl Biokhim Mikrobiol 29:280-285.
18. Kolpakov Al, Kupriianova-Ashina FG, Leshchinskaia IB. 2000. [Dependence of the effect of RNAase from Bacillus intermedius on the growth of baker's yeast on the concentration of the exogenous enzyme]. Mikrobiologiia 69:478-482.
19. Ilinskaya ON, Ivanchenko OB, Karamova NS. 1995. Bacterial ribonuclease: mutagenic effect in microbial test-systems. Mutagenesis 10:165-170.
20. Ilinskaya ON, Karamova NS, Ivanchenko OB, Kipenskaya LV. 1996. SOS-inducing ability of native and mutant microbial ribonucleases. Mutat Res 354:203-209.
21. Kurinenko BM, Sobchuk, LI, Haibullina, SA, Karpova SI. 1986. Antitumor activity of ribonuclease Bacillus intermedius7P. Exp Oncologiya 6: 54-57.
22. Kurinenko BM, Sergeeva EV, Sobchuk LI, Bulgakova RS, Haibullina SA. 1989. Study of toxicity of Bacillus intermedius RNase in vitro and in vivo. Antibiot i Khimioter 34:266-270.
23. Ilinskaya O, Decker K, Koschinski A, Dreyer F, Repp H. 2001. Bacillus intermedius ribonuclease as inhibitor of cell proliferation and membrane current. Toxicology 156:101-107.
24. Olmo N, Turnay J, Gonzalez de Butitrago G, Lopez de Silanes I, Gavilanes JG et al. 2001. Cytotoxic mechanism of the ribotoxin alpha-sarcin. Induction of cell death via apoptosis. Eur J Biochem 268:2113-2123.
25. Ca channels. Biochem Biophys Res Comm 314:550-554.
26. Abraham AT, Lin J, Newton DL, Rybak S, Hecht S. 2003. RNA cleavage and inhibition of protein synthesis by bleomycin. Chem Biol 10:45-52.
27. Makarov AA. Ilinskaya ON. 2003. Cytotoxic ribonucleases: molecular weapons and their targets. FEBS Lett 540:15-20.
28. Ran S, Downes A, Thorpe PE. 2002. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 62: 6132-6140.
29. Ilinskaya ON, Dreyer F, Mitkevich VA, Shaw KL, Pace CN et al. 2002. Changing the net charge from negative to positive makes ribonuclease Sa cytotoxic. Protein Sci 11:2522-2525.
30. Futami J, Maeda T, Kitazoe M, Nukui E, Tada H et al. 2001. Preparation of potent cytotoxic ribonucleases by cationization: enhanced cellular uptake and decreased interaction with ribonuclease inhibitor by chemical modification of carboxyl groups. Biochemistry 40:7518-7524.
31. Johnson RJ, Chao TY, Lavis LD, Raines RT. 2007. Cytotoxic ribonucleases: the dichotomy of Coulombic forces. Biochemistry 46:10308-10316.
32. Leich F, Stöhr N, Rietz A, Ulbrich-Hofmann R, Arnold U. 2007. Endocytotic internalization as a crucial factor for the cytotoxicity of ribonucleases. J. Biol Chem 282:27640-27646.
33. Navarro S, Aleu J, Jiménez M, Boix E, Cuchillo CM et al. 2008. The cytotoxicity of eosinophil cationic protein/ribonuclease 3 on eukaryotic cell lines takes place through its aggregation on the cell membrane. Cell Mol Life Sci 65:324-337.
34. Prior TI, FitzGerald DJ, Pastan I. 1992. Translocation mediated by domain II of Pseudomonas exotoxin A: transport of bamase into the cytosol. Biochemistry 31:3555-3559.
35. Rybak SM, Newton DL. 1999. Natural and engineered cytotoxic ribonucleases: therapeutic potential. Exp Cell Res 253:325-335.
36. Glinka EM, Edelweiss EF, Sapozhnikov AM, Deyev SM. 2006. A new vector for controllable expression of an anti-HER2/neu mini-antibody-bamase fusion protein in HEK 293T cells. Gene 366:97-103.
37. De Lorenzo C, Di Malta C, Cali G, Troise F, Nitsch L et al. 2007. Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent. FEBS Lett 581:296-300.
38. Hoshimoto S, Ueda M, Jinno H, Kitajima M, Futami J et al. 2006. Mechanisms of the growth-inhibitory effect of the RNase-EGF fused protein against EGFR-overexpressing cells. Anticancer Res 26:857-863.
39. Krauss J, Arndt MA, Vu BK, Newton DL, Seeber S et al. 2005. Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein. Biochem Biophys Res Commun 331:595-602.
40. Erickson HA, Jund MD, Pennell CA. 2006. Cytotoxicity of human RNase-based immunotoxins requires cytosolic access and resistance to ribonuclease inhibition. Protein Eng Des Sel 19:37-45.
41. Menzel C, Schirrmann T, Konthur Z, Jostock T, Dubel S. 2008. Human antibody RNase fusion protein targeting CD30+ lymphomas. Blood 111: 3830-3837.
42. Arnold U, Ulbrich-Hofmann R. 2006. Natural and engineered ribonucleases as potential cancer therapeutics. Biotechnol Lett 28:1615-1622.
43. Saxena SK, Sirdeshmukh R, Ardelt W, Mikulski SM, Shogen K et al. 2003. Entry into cells and selec!tive degradation of tRNAs by a cytotoxic member of the RNase A family. J. Biol Chem 277:15142-15146.
44. Saxena SK, Shogen K, Ardelt W. 2003. Onconase and its therapeutic potential. Lab Med 34:380-387.
45. Iordanov MS, Ryabinina OP, Wong J, Newton DL, Rybak SM et al. 2000. Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: Evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res 60:1983-1994.
46. Ardelt B, Ardelt W, Darzynkiewicz Z. 2003. Cytotoxic ribonucleases and RNA interference (RNAi). Cell Cycle 2:22-24.
47. Ilinskaya ON, Koschinski A, Repp H, Mitkevich VA, Dreyer F et al. 2008. RNase-induced apoptosis: Fate of calcium-activated potassium channels. Biochimie 90:717-725.
48. Sorrentino S, Naddeo M, Russo A, D'Alessio G. 2003. Degradation of double-stranded RNA by human pancreatic ribonuclease: Crucial role of noncatalytic basic amino acid residues. Biochemistry 42:10182-19190.
49. Blaszczyk J, Gan J, Tropea JE, Court DL, Waugh DS et al. 2004. Noncatalytic assembly of ribonuclease III with double-stranded RNA. Structure 12:457-466.
50. Rosenberg HF. 1995. Recombinant human eosinophil cationic protein. Ribonuclease activity is not essential for cytotoxicity. J. Biol Chem 270: 7876-7881.
51. Youle RJ, D'Alessio G. 1997. Antitumor RNases. In: D'Alessio G, Riordan JF, editors. Ribonucleases. Structure and Function 1997. Academic Press: NY 491-514.
52. Bracale A, Spalletti-Cernia D, Mastronicola M, Castaldi F, Mannucci R et al. 2002. Essential stations in the intracellular pathway of cytotoxic bovine seminal ribonuclease. Biochem J 362:553-560.
53. Hunter T. 1997 Oncoprotein networks review. Cell 88:333-346.
54. Biermann K, Göke F, Nettersheim D, Eckert D, Zhou H et al. 2007. c-KIT is frequently mutated in bilateral germ cell tumors and down-regulated during progression from intratubular germ cell neoplasia to seminoma. J. Pathol 213:311-318.
55. Ilinskaya ON, Zelenikhin PV, Petrushanko IYu, Mitkevich VA, Prassolov VS et al. 2007. Binase induces apoptosis of transformed myeloid cells and does not induce T-cell immune response. Biochem Biophys Res Comm 361:1000-1005.
56. + channel of intermediate conductance: a molecular target for novel treatments? Curr Drug Targets 2:401-422.
57. Lang F, Shumilina E, Ritter M, Gulbins E, Vereninov A et al. 2006. Ion channels and cell volume in regulation of cell proliferation and apoptotic cell death. Contrib Nephrol 152:142-160.
58. 2+ current. Biochim Biophys Acta 1269:57-63.
59. Morimoto T, Ohya S, Hayashi H, Onozaki K, Imaizumi Y. 2007. Cell-cycle-dependent regulation of Ca2+-activated K+ channel in Jurkat T-lymphocyte. J. Pharmacol Sci 104:94-98.
60. Spalletti-Cernia D, Sorrentino R, Di Gaetano S, Piccoli R, Santoro V et al. 2004. Highly selective toxic and proapoptotic effects of two dimeric ribonucleases on thyroid cancer cells compared to the effects of doxorubicin. Brit J Cancer Res 90:270-277.
61. Lee I, Kalota A, Gewirtz AM, Shogen K. 2007. Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice. Anticancer Res 27:299-307.
62. Schmitt CA. 2007. Cellular senescence and cancer treatment. Biochim Biophys Acta 1775:5-20.
63. Inouye M. 2006. The discovery of mRNA interferases: implication in bacterial physiology and application to biotechnology. Cell Physiol 209: 670-676.
64. Kamphuis MB, Monti MC, van den Heuvel RH, López-Villarejo J, Diaz-Orejas R et al. 2007. Structure and function of bacterial kid-kis and related toxin-antitoxin systems. Protein Pept Lett 14:113-124.
65. Andersen JB, Li XL, Judge CS, Zhou A, Jha BK et al. 2007. Role of 2-5A-dependent RNase-L in senescence and longevity. Oncogene 26: 3081-3088.
66. Bisbal C, Silverman RH. 2007. Diverse functions of RNase L and implications in pathology. Biochimie 89:789-798.
67. Halicka DH, Pozarowski P, Ita M, Ardelt WJ, Mikulski SM et al. 2002. Enhancement of activation-induced apoptosis of lymphocytes by the cytotoxic ribonuclease (ranpirnase). Int J Oncol 21:1245-1250.
68. Matousek J, Soucek J, Slavik T, Tománek M, Lee JE et al. 2003. Comprehensive comparison of the cytotoxic activities of onconase and bovine seminal ribonuclease. Comp Biochem Physiol C Toxicol Pharmacol 136:343-356.
69. Wu Y, Mikulski SM, Ardelt W, Rybak SM, Youle RJ. 1993. A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity. J. Biol Chem 268:10686-10693.
70. Shoemaker RH. 2006. The NC160 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813-823.
71. Brown JM, Wouters, BG. 1999. Apoptosis, p53, and tumor cell Sensitivity to anticancer agents. Cancer Res 59:1391-1399.
72. Haigis MC, Kurten EL, Raines RT. 2003. Ribonuclease inhibitor as an intracellular sentry. Nucleic Acids Res 31:1024-1032.
73. Leland P., Raines R. 2001. Cancer chemotherapy: Ribonucleases to the rescue. Chem. Biol 8:405-413.
74. Newton DL, Hansen HJ, Mikulski SM, Goldenberg DM, Rybak SM. 2001. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood 97:528-535.
75. Rodríguez M, Torrent G, Bosch M, Rayne F, Dubremetz JF et al. 2007. Intracellular pathway of onconase that enables its delivery to the cytosol. J. Cell Sci 120:1405-1411.
76. Kim BM, Kim H, Raines RT, Lee Y. 2004. Glycosylation of onconase increases its conformational stability and toxicity for cancer cells. Biochem Biophys Res Commun 315:976-983.
77. Leland PA, Staniszewski KE, Kim SM, Raines RT. 2001. Endowing human pancreatic ribonuclease with toxicity for cancer cells. J. Biol Chem 276:43095-43102.
78. Kraulis PJ. 1991. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J. Appl Crystallogr 24:7768-7773.